Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.

Hypersensitivity reactions to non-steroidal anti-inflammatory drugs (NSAIDs) have been classified as immediate (or acute) and delayed. Immediate reactions can be further classified into 4 clinical types: NSAID-exacerbated respiratory disease (N-ERD), NSAID-exacerbated cutaneous disease (NECD), NSAID-induced urticaria/angioedema (NIUA), and single NSAID-induced urticaria/angioedema/anaphylaxis (SNIUAA). Specifically, the NIUA type references reactions to ≥2 NSAIDs belonging to different chemical groups, involving urticaria and/or angioedema in patients with no underlying chronic spontaneous urticaria.

Recurrences of anaphylaxis: trends and risk factors.

Purpose Of Review: Recurrences of anaphylaxis is a concern due to its unpredictability and long-term burden to patients and healthcare systems. This review examines recurrence rates, associated risk factors, and gaps in current knowledge to guide improved clinical management.

Recent Findings: From 1240 initial records, 11 studies fulfilled the inclusion criteria of our systematic review.

Development of a Risk-Stratification Tool for Nonsteroidal Anti-Inflammatory Drug Hypersensitivity on a Large Cohort.

Background: A risk stratification tool for nonsteroidal anti-inflammatory drugs (NSAIDs) hypersensitivity is currently lacking.

Objective: To develop and validate a risk stratification tool for NSAID hypersensitivity.

Methods: We conducted a retrospective study of subjects presenting between February 2001 and December 2020 at the Allergy Unit of the University Hospital of Montpellier, with a history of hypersensitivity to NSAIDs.

Exploring the pathogenesis and clinical implications of asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap (ACO): a narrative review.

The complexity and diversity of the immune response in patients with asthma, chronic obstructive pulmonary disease (COPD), and asthma-COPD overlap present significant challenges for disease management. Relying on a limited number of biomarkers and clinical data is insufficient to fully reveal the immunopathogenesis of these diseases. However, technologies such as cell analysis, cytokine investigation, and nucleic acid sequencing have provided new insights into the underlying mechanisms of these diseases, leading to the discovery of several biomarkers-including cell degranulation, cell function, secreted cytokines, and single nucleotide polymorphisms-that have potential clinical implications.